Molecular Cancer,
Journal Year:
2019,
Volume and Issue:
18(1)
Published: Dec. 1, 2019
N6-methyladenosine
(m6A)
is
methylation
that
occurs
in
the
N6-position
of
adenosine,
which
most
prevalent
internal
modification
on
eukaryotic
mRNA.
Accumulating
evidence
suggests
m6A
modulates
gene
expression,
thereby
regulating
cellular
processes
ranging
from
cell
self-renewal,
differentiation,
invasion
and
apoptosis.
M6A
installed
by
methyltransferases,
removed
demethylases
recognized
reader
proteins,
regulate
RNA
metabolism
including
translation,
splicing,
export,
degradation
microRNA
processing.
Alteration
levels
participates
cancer
pathogenesis
development
via
expression
tumor-related
genes
like
BRD4,
MYC,
SOCS2
EGFR.
In
this
review,
we
elaborate
recent
advances
research
enzymes.
We
also
highlight
underlying
mechanism
progression.
Finally,
review
corresponding
potential
targets
therapy.
Molecular Cancer,
Journal Year:
2020,
Volume and Issue:
19(1)
Published: May 12, 2020
Abstract
N6-methyladenosine
(m6A)
is
considered
the
most
common,
abundant,
and
conserved
internal
transcript
modification,
especially
in
eukaryotic
messenger
RNA
(mRNA).
m6A
installed
by
methyltransferases
(METTL3/14,
WTAP,
RBM15/15B,
VIRMA
ZC3H13,
termed
“writers”),
removed
demethylases
(FTO,
ALKBH5,
ALKBH3,
“erasers”),
recognized
m6A-binding
proteins
(YTHDC1/2,
YTHDF1/2/3,
IGF2BP1/2/3,
HNRNP,
eIF3,
“readers”).
Accumulating
evidence
suggests
that
methylation
greatly
impacts
metabolism
involved
pathogenesis
of
many
kinds
diseases,
including
cancers.
In
this
review,
we
focus
on
physiological
functions
modification
its
related
regulators,
as
well
potential
biological
roles
these
elements
human
tumors.
Molecular Cancer,
Journal Year:
2022,
Volume and Issue:
21(1)
Published: Jan. 12, 2022
Abstract
Metabolic
reprogramming
is
one
of
the
main
characteristics
malignant
tumors,
which
due
to
flexible
changes
cell
metabolism
that
can
meet
needs
growth
and
maintain
homeostasis
tissue
environments.
Cancer
cells
obtain
metabolic
adaptation
through
a
variety
endogenous
exogenous
signaling
pathways,
not
only
promote
cancer
cells,
but
also
start
transformation
process
adapt
tumor
microenvironment.
Studies
show
m6A
RNA
methylation
widely
involved
in
recombination
cells.
In
eukaryotes,
most
abundant
modification
mRNA,
almost
all
cycle
stages,
including
regulation
transcription,
maturation,
translation,
degradation
stability
mRNA.
M6A
be
physiological
pathological
processes,
cancer.
this
review,
we
discuss
role
plays
metabolism-related
molecules
aiming
importance
targeting
regulating
metabolism.
Molecular Cancer,
Journal Year:
2021,
Volume and Issue:
20(1)
Published: Jan. 18, 2021
Abstract
RNA
modifications
have
recently
emerged
as
critical
posttranscriptional
regulators
of
gene
expression
programmes.
Significant
advances
been
made
in
understanding
the
functional
role
regulating
coding
and
non-coding
processing
function,
which
turn
thoroughly
shape
distinct
They
affect
diverse
biological
processes,
correct
deposition
many
these
is
required
for
normal
development.
Alterations
their
are
implicated
several
diseases,
including
cancer.
In
this
Review,
we
focus
on
occurrence
N
6
-methyladenosine
(m
A),
5-methylcytosine
5
C)
pseudouridine
(Ψ)
RNAs
describe
physiopathological
We
will
highlight
latest
insights
into
mechanisms
how
influence
tumour
development,
maintenance,
progression.
Finally,
summarize
development
small
molecule
inhibitors
that
target
specific
writers
or
erasers
to
rewind
epitranscriptome
a
cancer
cell
therapeutic
potential.
Molecular Cancer,
Journal Year:
2022,
Volume and Issue:
21(1)
Published: Feb. 14, 2022
Abstract
Abnormal
N6-methyladenosine
(m6A)
modification
is
closely
associated
with
the
occurrence,
development,
progression
and
prognosis
of
cancer,
aberrant
m6A
regulators
have
been
identified
as
novel
anticancer
drug
targets.
Both
traditional
medicine-related
approaches
modern
discovery
platforms
used
in
an
attempt
to
develop
m6A-targeted
drugs.
Here,
we
provide
update
latest
findings
on
critical
roles
cancer
progression,
summarize
rational
sources
for
agents
from
medicines
computer-based
chemosynthetic
compounds.
This
review
highlights
potential
targeting
treatment
proposes
advantage
artificial
intelligence
(AI)
m6A-targeting
Graphical
abstract
Three
stages
discovery:
medicine-based
natural
products,
chemical
or
synthesis,
(AI)-assisted
future.
Journal of Hematology & Oncology,
Journal Year:
2020,
Volume and Issue:
13(1)
Published: April 10, 2020
Abstract
N
6
-methyladenosine
(m
A)
is
a
well-known
post-transcriptional
modification
that
the
most
common
type
of
methylation
in
eukaryotic
mRNAs.
The
regulation
m
A
dynamic
and
reversible,
which
erected
by
methyltransferases
(“writers”)
removed
demethylases
(“erasers”).
Notably,
effects
on
targeted
mRNAs
resulted
predominantly
depend
functions
different
A-binding
proteins
(“readers”)
including
YT521-B
homology
(YTH)
domain
family,
heterogeneous
nuclear
ribonucleoproteins
(HNRNPs),
insulin-like
growth
factor
2
mRNA-binding
(IGF2BPs).
Indeed,
readers
not
only
participate
multiple
procedures
RNA
metabolism,
but
also
are
involved
variety
biological
processes.
In
this
review,
we
summarized
specific
underlying
mechanisms
tumorigenesis,
hematopoiesis,
virus
replication,
immune
response,
adipogenesis.
Cell Death and Disease,
Journal Year:
2020,
Volume and Issue:
11(10)
Published: Oct. 24, 2020
Abstract
N6-methyladenosine
(m
6
A)
serves
as
the
most
common
and
conserved
internal
transcriptional
modification.
However,
roles
of
m
A
on
cervical
cancer
(CC)
tumorigenesis
are
still
unclear.
Here,
results
indicated
that
METTL3
was
significantly
upregulated
in
CC
tissue
cells,
which
closely
correlated
with
lymph
node
metastasis
poor
prognosis
patients.
MeRIP-Seq
analysis
revealed
profiles
cells.
Functionally,
promoted
proliferation
Warburg
effect
(aerobic
glycolysis)
Mechanistically,
targeted
3’-Untranslated
Region
(3’-UTR)
hexokinase
2
(HK2)
mRNA.
Moreover,
recruited
YTHDF1,
a
reader,
to
enhance
HK2
stability.
These
findings
demonstrated
enhanced
stability
through
YTHDF1-mediated
modification,
thereby
promoting
CC,
might
promote
novel
insight
for
treatment.
Journal of Experimental & Clinical Cancer Research,
Journal Year:
2020,
Volume and Issue:
39(1)
Published: Sept. 29, 2020
Abstract
Background
N6-Methyladenosine
(m6A)
modification
has
been
implicated
in
multiple
processes
for
colon
cancer
development.
IGF2BP3
was
a
newly
reported
m6A
reader,
whereas
its
role
remains
unclear.
Methods
The
expression
of
associated
enzymes
and
total
level
were
measured
by
Western
Blotting
analysis
RNA
Methylation
Quantification
Kit
respectively.
Cell
cycle
analyzed
flowcytometry.
interaction
related
targets
immunoprecipitation
(RIP)
(MeRIP)
assays.
Results
We
investigated
all
regulated
found
only
the
overexpression
with
progression
survival
based
on
Cancer
Genome
Atlas
(TCGA)
databases.
Additionally,
we
also
demonstrated
DNA
replication
cell
cycle.
Knockdown
significantly
repressed
percentage
S
phase
as
well
proliferation.
Further
research
bound
to
mRNA
Cyclin
D1
(CCND1,
checkpoint
G1/S
cycle)
reduced
stability
via
reading
CDS
region.
Overexpression
down-regulated
cells
completely
rescued
inhibited
similar
at
VEGF.
VEGF
reads
modification,
thus
both
mRNA.
angiogenesis
regulating
Conclusion
CCND1
possible
prognosis
marker
potential
therapeutic
target
cancer.
Molecular Cancer,
Journal Year:
2020,
Volume and Issue:
19(1)
Published: March 2, 2020
Abstract
As
the
standard
treatments
for
cancer,
chemotherapy
and
radiotherapy
have
been
widely
applied
to
clinical
practice
worldwide.
However,
resistance
cancer
therapies
is
a
major
challenge
in
clinics
scientific
research,
resulting
tumor
recurrence
metastasis.
The
mechanisms
of
therapy
are
complicated
result
from
multiple
factors.
Among
them,
non-coding
RNAs
(ncRNAs),
along
with
their
modifiers,
investigated
play
key
roles
regulating
development
mediating
within
various
cancers,
such
as
hepatocellular
carcinoma,
breast
lung
gastric
etc.
In
this
review,
we
attempt
elucidate
underlying
ncRNA/modifier-modulated
radiotherapy,
providing
some
therapeutic
potential
points
future
treatment.
